NCT07258719 is a NA clinical trial of Essential Oil 1 in Anxiety, sponsored by Jenalee Hinds.

Who is sponsoring NCT07258719?

NCT07258719 is sponsored by Jenalee Hinds.

What drugs are being tested in NCT07258719?

Interventions in NCT07258719: Essential Oil 1, Essential Oil 2.

Is NCT07258719 still recruiting?

NCT07258719 is currently completed. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT07258719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aromatherapy's Impact on Test Anxiety in College Students: A Mixed Methods Study

Completed NA Last updated 2 February 2026

What this trial tests

NA trial testing Essential Oil 1 in Anxiety in 20 participants. Completed in 18 December 2025.

Timeline

18 September 2025

Primary endpoint
18 December 2025

18 December 2025

Quick facts

Lead sponsor	Jenalee Hinds
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	18 September 2025
Primary completion	18 December 2025
Estimated completion	18 December 2025
Sites	1 location across United States

Drugs / interventions tested

Essential Oil 1
Essential Oil 2

Conditions studied

Anxiety — all drugs for Anxiety →

Sponsor

Jenalee Hinds

Who can join

Adults 18 to 99, any sex, with Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effectiveness of aromatherapy as an intervention to reduce test anxiety and improve academic performance. The Investigators hypothesize that exposure to aromatherapy during assessments will lead to lower levels of test anxiety and result in higher quiz and test scores.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07258719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jenalee Hinds
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07258719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing